$RLFTF RELIEF ANNOUNCES NOTICE OF ANNUAL GENERAL MEETING OF

New Post Public Reply Private Reply Replies (0) Message Board
mc67
390
$RLFTF RELIEF ANNOUNCES NOTICE OF ANNUAL GENERAL MEETING OF RELIEF THERAPEUTICS HOLDING AG 27 May 2021

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG

Geneva, Switzerland, May 27, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company" , a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives notice of the Annual General Meeting (AGM) of shareholders to be held on June 18, 2021.

As a result of the exceptional circumstances due to the coronavirus pandemic, the AGM will be held without the physical presence of shareholders in accordance with article 27 of the Ordinance 3 on Measures to Combat the Coronavirus. Guidelines on how to deliver voting instructions can be found in the AGM formal invitation, which is being sent out today to registered shareholders.
Agenda items:

1. Approval of the Annual Report, Statutory Financial Statements (balance sheet, income statement and notes) and Consolidated Financial Statements for the year 2020, Statutory Auditors' Report

2. Appropriation of Results

3. Discharge of the members of the Board of Directors and of the Executive Committee

4. Increase of the authorized share capital

5. Increase of the conditional share capital

6. Votes on the compensation of the members of the Board of Directors and of the Executive Committee

7.1 Re-election of existing members of the Board of Directors

7.2 Election of new members of the Board of Directors - Dr. Patrice P. Jean and Paolo Galfetti

7.3 Re-election of the Chairman of the Board of Directors

7.4 Re-election of the members of the Nomination and Compensation Committee

7.5 Re-election of the Independent Voting Rights Representative

7.6 Re-election of the Auditors

The full agenda is available for download on the Company’s website (https://relieftherapeutics.com/investor-relations).

The Board of Directors recommends that the General Meeting approves the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for the year ended 31 December 2020.

The Board of Directors proposes to carry forward the loss for the year 2020 in the amount of CHF 20'009'867.

The Board of Directors recommends that the General Meeting grants discharge to the members of the Board of Directors and of the Executive Committee.
Increase of authorized capital and of conditional share capital

The authorized share capital is intended for the future financing of the Company, as required in connection with future projects as well as for responding quickly to strategic business opportunities.

The Board of Directors proposes to maintain an authorized share capital of around but not more than 50% of the ordinary share capital and, therefore, to increase the amount of the existing authorized share capital from CHF 11'250'000.00 to CHF 16'850'000.00.

Like the authorized share capital, conditional capital 3b2 provides the Company with the flexibility to quickly obtain financing but allows for the use of certain financial instruments carrying derivative features.

The Board of Directors proposes to maintain a total conditional share capital of around but not more than 50% of the ordinary share capital and, therefore, to increase the amount of the existing conditional share capital from CHF 2'533'413.33 to CHF 15'630'000.00.

Votes on the compensation of the members of the Board of Directors and of the Executive Committee

The Board of Directors recommends a maximum amount of CHF 1'500'000 (both fixed and variable compensation, including stock options and other, but excluding employer social security contributions) for the members of the Board of Directors for the period from the 2021 AGM until the 2022 AGM and a maximum total compensation of CHF 5'000'000 for the members of the Executive Committee for the financial year 2022.

These compensation amounts are the same amounts approved by the December 2020 Extraordinary General Meeting for the prior period (from the 2020 AGM until the 2021 AGM for the Board compensation and for financial year 2021 for the Executive Committee compensation).

The Board of Directors proposes to re-elect: (i) the members of the Board of Directors (Dr. Raghuram Selvaraju and Dr. Thomas Plitz), (ii) the members of the Nomination and Compensation Committee (Dr. Raghuram Selvaraju and Dr. Thomas Plitz), (iii) the Chairman of the Board of Directors (Dr. Raghuram Selvaraju), (iv) the Independent Voting Rights Representative (Thomas Hua), and (v) the Auditors (MAZARS SA).

Election of Dr. Patrice P. Jean as new member of the Board of Directors
Dr. Patrice P. Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City.

She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations. Dr. Jean graduated summa cum laude from Xavier University of Louisiana in 1993 with a degree in biochemistry, and she holds a Ph.D. in molecular biology from Princeton University.

She graduated from Columbia University School of Law in 2002, where she was Editor-in-Chief of the Columbia Science & Technology Law Review. Dr. Jean currently serves as Vice-President of the New York Intellectual Property Law Education Foundation and is a Board member of the New York Intellectual Property Law Association.

Election of Paolo Galfetti as new member of the Board of Directors
Paolo Galfetti is the Chief Executive Officer of APR Applied Pharma Research S.A. (APR). Under the recently signed binding term sheet between Relief and APR, APR is entitled to appoint a designee to serve on the Relief Board of Directors. Mr. Galfetti has over twenty years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development.
He joined APR in 1995 as head of licensing and business development and was appointed Chief Executive Officer (CEO) in 2002. Under his leadership, APR has brought its first product onto the market and developed a rich pipeline of product candidates. He also was a founding partner, CEO and board member of the Institute for Pharmacokinetic and Analytical Studies AG (IPAS), a Swiss contract research organization (CRO), as well as CEO and board member of Farma Resa s.r.l., an Italian CRO. Mr. Galfetti is a Chartered Financial Analyst (CFA) and has a bachelor’s degree in economics from the Commercial University Bocconi, Milan, Italy. He is a member of several pharma licensing groups.

###

ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.

Contact:
CONTACT:

RELIEF THERAPEUTICS Holding AG:
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
contact@relieftherapeutics.com
For media inquiries contact:
MEDIA/INVESTOR CONTACT:
MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
relief@mc-services.eu


https://www.relieftherapeutics.com/newsblog/r...holding-ag

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 135

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 17

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 134

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 211

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 28

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Latham Group's Stock Target Rises: A Positive Outlook Ahead

Updated Category News Views 101

Stifel Holds a Positive View on Latham Group Inc. Stifel has recently reaffirmed its Buy rating for Latham Group Inc. (NASDAQ:SWIM) and bumped its price target to $7.00, up from the previous $6.80. This decision is fueled by upcoming investor meetings led by Latham Group's CEO, Scott Rajeski, and CFO, Oliver Gloe. These meetings aim to provide crucial insights into the...

Continue Reading
Keeper Delivers Undeniable Improvements in Account Management

Updated Category News Views 135

Keeper Introduces Instant Account Switching and Passkey Enhancements Keeper Security has recently unveiled a significant upgrade to its mobile applications and browser extension. This update is set to enhance user experience by introducing instant account switching and vital passkey features that make accessing different accounts faster than ever. Seamless Account...

Continue Reading
Sagard Real Estate Ventures into Growth with New Fund

Updated Category News Views 311

Sagard Real Estate Expands Portfolio with New Acquisition Sagard Real Estate, the firm formerly known as EverWest Real Estate Investors, is making waves in the real estate market with its recent acquisition of Vista Imperio. This strategic investment involves a 158-unit suburban garden-style multifamily property, marking a significant step forward for the company in its...

Continue Reading
Celebrating a Decade of Leadership in Complexity and Execution

Updated Category News Views 160

Reflecting on 10 Years of Team of Teams A decade ago, the revolutionary ideas presented in General Stanley McChrystal’s book, Team of Teams: New Rules of Engagement for a Complex World, emerged as a guiding light for leaders navigating complex environments. The principles outlined in this book have proven to be increasingly vital in today’s fast-paced world. Team of...

Continue Reading
Hakeem's Nomination Showcase for FinTech Excellence in 2024

Updated Category News Views 65

Hakeem Earns Recognition at the Singapore FinTech Festival Walee Group is thrilled to announce that its innovative product, Hakeem, has been nominated for the prestigious Singapore FinTech Festival - FinTech Excellence Awards. This accolade highlights the commitment of Walee Financial Services in developing solutions that enhance financial accessibility, particularly for...

Continue Reading